Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of Laboratorios HIPRA.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Laboratorios HIPRA
Spain_new Flag
Country
Country
Spain
Address
Address
Avda. la Selva 135 17170 Amer (Girona)
Telephone
Telephone
(+34) 972 43 06 60
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

The agreement aims for the commercialisation of HIPRA's mRNA COVID-19 vaccine, Bimervax, which combines a part of the SARS-CoV-2 virus spike protein with an adjuvant, in the United Kingdom.


Lead Product(s): Recombinant, Adjuvanted Covid-19 Vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Bimervax

Highest Development Status: ApprovedProduct Type: Vaccine

Recipient: Accord healthcare

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement August 04, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Bimervax is a recombinant protein vaccine whose active substance is SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer – B.1.351-B.1.1.7 strains, it provides immune response at humoral and cellular level, against the COVID-19.


Lead Product(s): Recombinant Protein Covid-19 Vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Bimervax

Highest Development Status: ApprovedProduct Type: Vaccine

Partner/Sponsor/Collaborator: Veristat

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 25, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Bimervax is a recombinant protein vaccine whose active substance is SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer – B.1.351-B.1.1.7 strains, it provides immune response at humoral and cellular level, against the COVID-19.


Lead Product(s): Recombinant Protein Covid-19 Vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Bimervax

Highest Development Status: ApprovedProduct Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Messenger RNA based Covid Vaccine is an adjuvanted recombinant protein vaccine based on a receptor-binding domain (RBD) fusion heterodimer containing variants alpha and beta of SARS-CoV-2 is authorized for phase III clinical trial.


Lead Product(s): Adjuvanted Recombinant Protein Vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase IIProduct Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 01, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The main objectives of the Phase IIb trial are to confirm safety and tolerability for a booster dose and to check if the booster dose prolongs the immune response to Covid-19 in people who have already been vaccinated.


Lead Product(s): Messenger RNA Based Covid Vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase IIProduct Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 15, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY